The development of autoantibodies targeting ADAMTS13 has also been reported in response to some therapies (e.g. ticlopidine, clopidogrel, immune checkpoint inhibitors) and is then referred to as drug-associated thrombotic thrombocytopenic purpura [114]. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.